Admedus Ltd was established in June 2011, through the merger of Allied Medical Ltd an unlisted public company and bioMD Ltd an ASX listed company (ASX: BOD). The merger created a diversified healthcare group with assets in research & development, products in advanced clinical trials ready for commercialisation and a successful sales, marketing and medical device distribution business.
Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Kindbody is a health and technology company focused on providing comprehensive fertility services tailored for modern women. Their offerings include intrauterine insemination, in-vitro fertilization, egg and embryo freezing, as well as support for donors. In addition to fertility treatments, Kindbody provides a range of holistic health services, including maternity care, gynecology, and wellness support. By leveraging modern technology, Kindbody aims to improve access to affordable healthcare, ensuring that women can receive quality services that enhance their overall health and wellbeing.
Private Equity Round in 2021
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.
Juno Diagnostics, Inc. is a health technology company based in San Diego, California, focused on democratizing access to genetic information. Established in 2017, Juno specializes in cell-free DNA-based prenatal testing and is also engaged in the development of genetic testing tools for various applications, including epigenetics, inherited diseases, and cancer diagnostics. The company aims to create simple and cost-effective devices that facilitate point-of-need genetic testing, thereby enhancing accessibility to vital health information.
Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, specializing in clinical solutions for neurointerventional procedures. Founded in 2013, the company offers an innovative portfolio that includes products such as high flow tubing, various guide and diagnostic catheters, and aspiration pumps. MIVI's devices are designed to enhance patient outcomes by improving the safety and efficacy of treatments for ischemic stroke, facilitating the removal of obstructions and restoring blood flow. By focusing on reducing complications and procedure times, MIVI aims to expand treatment options for a broader range of patients, ultimately advancing the field of neurointervention.
Earli is focused on transforming cancer detection and treatment by developing innovative technologies that enable early identification of tumors. The company specializes in creating synthetic biopsies, which are designed to induce cancer cells to produce non-human synthetic biomarkers. These biomarkers can be detected in biological samples such as blood, urine, or breath, allowing for the visualization of tumors that are typically too small to identify in traditional screenings. By leveraging these programmable genetic constructs, Earli aims to provide real-time data on cancer presence and progression, facilitating personalized treatment approaches and improving the chances of successful intervention. Overall, Earli's mission is to make the experience of cancer more manageable by ensuring timely detection and response.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Adagio Medical specializes in the design and manufacture of medical devices aimed at treating cardiac arrhythmias. Founded in 2011 and based in Laguna Hills, California, the company is dedicated to the research and development of innovative cryoablation catheters. These devices are engineered to create safe, continuous, transmural lesions that effectively address various cardiac conditions, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical's product offerings include the continuous lesion ablation system (iCLAS), specialized catheters, esophageal balloons, and consoles, all developed to enhance the capabilities of electrophysiologists in the treatment of cardiovascular diseases.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.
I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine.
The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.
Metabolon was founded in 2000 and headquartered in Durham, North Carolina.
Kindbody is a health and technology company focused on providing comprehensive fertility services tailored for modern women. Their offerings include intrauterine insemination, in-vitro fertilization, egg and embryo freezing, as well as support for donors. In addition to fertility treatments, Kindbody provides a range of holistic health services, including maternity care, gynecology, and wellness support. By leveraging modern technology, Kindbody aims to improve access to affordable healthcare, ensuring that women can receive quality services that enhance their overall health and wellbeing.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.
CereVasc, Inc. is a medical device company that specializes in creating innovative and minimally invasive treatments for neurological diseases. The company has developed the eShunt System, an endovascularly deliverable cerebrospinal fluid shunt designed to replace traditional invasive surgical procedures for treating communicating hydrocephalus. This system aims to eliminate the need for general anesthesia and hospitalization, which are typically required for current treatments, such as ventriculo-peritoneal shunts. By providing a less invasive option, CereVasc seeks to improve patient outcomes and reduce the overall costs associated with surgical treatments for this serious condition. Founded in 2014, the company is headquartered in Auburndale, Massachusetts.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Private Equity Round in 2020
Sonendo, Inc. is a medical technology company that focuses on advancing dental care through innovative devices for root canal therapy. Based in Laguna Hills, California, Sonendo has developed the GentleWave® System, which enhances the cleaning and disinfection of tooth canals, improving clinical outcomes and efficiency compared to traditional methods. The company operates primarily through two segments: the Product segment, which includes sales of the GentleWave System and its related instruments, and the Software segment, which encompasses TDO® Software—widely recognized as a leading practice management solution for endodontics. Since its incorporation in 2006, Sonendo has aimed to transform dentistry by promoting effective treatments that preserve tooth structure and enhance patient care.
Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Kindbody is a health and technology company focused on providing comprehensive fertility services tailored for modern women. Their offerings include intrauterine insemination, in-vitro fertilization, egg and embryo freezing, as well as support for donors. In addition to fertility treatments, Kindbody provides a range of holistic health services, including maternity care, gynecology, and wellness support. By leveraging modern technology, Kindbody aims to improve access to affordable healthcare, ensuring that women can receive quality services that enhance their overall health and wellbeing.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Medicrea International SA specializes in the design, manufacture, and distribution of spinal implants, operating both in France and internationally. Established in 1990 and headquartered in Rillieux-la-Pape, France, the company offers a comprehensive range of products, including various systems for thoraco-lumbar fixation, cervical interbody devices, and specialized implants for treating conditions such as scoliosis, degenerative diseases, and trauma. Notable product lines include the PASS series, which encompasses polyaxial and posterior fixation systems, as well as the IMPIX series, featuring sterile PEEK Optima cervical and lumbar interbody devices. Medicrea focuses on delivering innovative technologies aimed at improving patient outcomes and supporting healthcare professionals in surgical procedures. The company has been dedicated to advancing spinal care, leveraging over 18 years of experience in the field. As of late 2020, Medicrea operates as a subsidiary of Covidien Group S.a.r.l.
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California.
Counsyl is a health technology company specializing in DNA screening for individuals and families. Its services aim to provide critical health information that can influence important decisions regarding behavior, prevention, and preparedness for future health challenges. By leveraging advanced technology, including custom-built robotics and a team of scientists and engineers, Counsyl processes blood and saliva samples with high precision and efficiency. The company has screened over 500,000 patients and collaborated with more than 6,000 healthcare professionals, striving to make DNA screening accessible to a broad audience. Counsyl’s innovative approach has earned recognition, including the Wall Street Journal’s Innovation Award for Medicine, and its Family Prep Screen has significantly aided individuals in understanding crucial genetic information prior to childbearing. The platform has expanded its offerings to include informed pregnancy and cancer screening, emphasizing the integration of sophisticated technology in real-time communication of medical results between patients and healthcare providers.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company is based in Fort Lauderdale, Florida.
Establishment Labs is a medical technology company headquartered in Alajuela, Costa Rica, specializing in the design, development, manufacturing, and marketing of silicone-filled breast and body shaping implants, primarily under the Motiva Implants brand. The company offers a diverse range of breast implants with various options for surface, shape, size, base, and projection. In addition to implants, Establishment Labs provides advanced solutions such as the Divina 3D surgical simulation system for pre-surgical consultations and the Puregraft technology for autologous fat harvesting and redistribution. The company operates globally, selling its products through exclusive distributors and a direct sales force in over 80 countries, while maintaining compliance with both FDA and ISO standards. Establishment Labs emphasizes innovation and quality assurance throughout its manufacturing processes, ensuring that its products meet the highest safety and performance standards.
VitalConnect specializes in wearable biosensor technology aimed at enhancing patient monitoring both in hospitals and remotely. The company utilizes its expertise in biomedical engineering, data analytics, and chip design to develop products that continuously monitor vital signs through an adhesive patch. These innovations include the Vista Solution, which provides healthcare professionals with 24/7 access to patient health data via an online portal, tracking 11 vital signs and offering predictive analytics. The VitalPatch biosensor specifically measures critical parameters such as EKG, heart rate, respiratory rate, and body temperature, facilitating immediate responses to urgent health situations. By combining these technologies, VitalConnect's solutions improve patient mobility and comfort while enabling clinicians to optimize treatment through comprehensive patient insights, ultimately leading to better health outcomes and reduced economic burdens.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Alliqua BioMedical, a regenerative technologies company based in Yardley, Pennsylvania, specializes in the development, manufacturing, and marketing of innovative medical products for soft tissue repair and replacement. The company offers a range of proprietary products, including MIST Ultrasound Healing Therapy, a noncontact low-frequency ultrasound treatment that promotes healing, and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, both of which are human biologic regenerative technologies. Additionally, Alliqua markets wound dressings such as SilverSeal Hydrogel, an antimicrobial option, and Hydress, a moist wound dressing. The company also provides contract manufacturing services for high water content hydrogels used in various applications, including wound care, medical diagnostics, and transdermal drug delivery. Alliqua aims to advance its projects in active ingredients and transdermal drug delivery systems as well as enhance its presence in advanced wound care solutions.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.